0001280784-26-000042
SEC filingNotes show $2.3B debt against $4.6B investments, $174.7M dividends paid, $48.2M cash; no segment reporting beyond portfolio industry mix.
As of June 30, 2026, cash and cash equivalents were $48.2M, with restricted cash of $2.3M. Total assets stood at $4,688.1M, and net assets at $2,274.3M (NAV per share $12.15). Debt (net of issuance costs) was $2,335.2M, up from $2,286.4M at December 31, 2025, driven by $1,078.8M of borrowings and $1,028.7M of repayments.
The Notes reference unfunded contractual commitments in the Schedule of Investments (footnote 17), but the aggregate commitment amount is not provided in the excerpt. The cash flow statement shows $0.2M of unearned fees related to unfunded commitments.
Dividends: $0.47 per share quarterly, $0.94 for six months, totaling $174.7M. Debt activity: $1,078.8M issued and $1,028.7M repaid, resulting in a net $50.1M increase in debt before costs. No buyback program was disclosed.
The company operates as a single segment. The Schedule of Investments provides industry concentrations: largest industries are Application Software (48.94% of net assets), Drug Discovery & Development (43.21%), Healthcare Services (37.92%), System Software (16.10%), etc. No segment-level operating income is reported.